Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Pre-transplant recipient evaluation (bmt)
Pre-transplant recipient evaluation (BMT) is the multi-specialty clinical assessment patients undergo before bone marrow transplantation. It checks organ function, infection status, disease remission, and psychological readiness to confirm transplant eligibility and reduce conditioning risks. This guide explains key tests, medical clearance criteria, approximate international costs, timelines in Turkey, potential complications, and questions to ask your transplant team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Pre-Transplant Recipient Evaluation (BMT)
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is pre-transplant recipient evaluation (bmt) and how does it work?
Pre-transplant recipient evaluation (bmt) is the comprehensive clinical, laboratory, and organ function assessment that every patient undergoes before receiving a bone marrow or hematopoietic stem cell transplant. Bone marrow transplantation (BMT) requires high-dose chemotherapy, immunotherapy, or total body irradiation—collectively termed conditioning therapy—to eradicate diseased marrow and suppress the immune system so donor or autologous stem cells can engraft. Because conditioning places severe physiological demands on every major organ, the recipient must be thoroughly evaluated to confirm that their body can withstand treatment.
The evaluation is not a single test but a multidisciplinary diagnostic workup coordinated by haematologists, cardiologists, pulmonologists, infectious disease specialists, nephrologists, and dental surgeons. Over several days, the team evaluates the heart, lungs, kidneys, liver, active infections, disease status, and psychological resilience. Undergoing pre-transplant recipient evaluation (bmt) in Turkey allows international patients to complete these rigorous multidisciplinary tests within a single dedicated centre before definitive admission. For patients exploring wider cancer therapies, our guide to oncology treatments in Turkey outlines available modalities and cellular therapy services.
What tests are included in the pre-transplant recipient workup?
The pre-transplant protocol follows standardized international guidelines established by organizations such as the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Transplantation and Cellular Therapy (ASTCT). The diagnostic batteries are grouped into distinct clinical domains:
- Cardiovascular clearance: Resting 12-lead electrocardiogram (ECG) and transthoracic echocardiogram to measure left ventricular ejection fraction (LVEF). Patients with cardiac history may require myocardial perfusion scintigraphy or cardiac MRI.
- Pulmonary function: Comprehensive pulmonary function tests (PFTs), including spirometry (FEV1, FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), alongside high-resolution chest computed tomography (HRCT) to exclude silent infections or structural lung disease.
- Renal and hepatic profiling: Serum creatinine, blood urea nitrogen, electrolytes, 24-hour urine creatinine clearance or isotopic GFR measurement, total bilirubin, transaminases, alkaline phosphatase, and coagulation profiles.
- Infectious disease serology: Comprehensive screening for cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B and C, human immunodeficiency virus (HIV), toxoplasmosis, syphilis, and latent tuberculosis (QuantiFERON assay).
- Disease restaging and bone marrow status: Bone marrow aspirate and trephine biopsy with flow cytometry, cytogenetics, and minimal residual disease (MRD) testing to confirm the exact remission depth before transplant.
- Dental and focal infection clearance: Full clinical dental examination and panoramic dental X-rays (orthopantomogram) to identify and treat asymptomatic cavities or periodontal disease before immunosuppression.
Does pre-transplant assessment improve transplant outcomes?
Clinical evidence demonstrates that thorough pre-transplant evaluation directly improves survival by identifying subclinical organ dysfunction and unrecognised infections that would otherwise cause fatal toxicities during conditioning. Rather than serving merely as an administrative gatekeeper, the workup provides the haematology team with the objective physiological data required to customise the transplant approach.
Haematologists rely on validated scoring tools, most notably the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Clinical trials have confirmed that higher HCT-CI scores correlate with increased non-relapse mortality (NRM). By quantifying pre-existing heart, lung, or kidney vulnerabilities, clinicians can adjust chemotherapy dosages, switch from toxic regimens to gentler non-myeloablative conditioning, or delay the transplant until an acute issue, such as a hidden dental abscess or latent viral reactivation, is completely resolved. The evidence shows that preparing the patient physiologically before admission substantially lowers transplant-related morbidity.
Pre-transplant recipient evaluation (bmt) cost in Turkey compared with the UK, US and Germany
The table below outlines approximate cost ranges for complete pre-transplant recipient evaluation across key medical travel destinations. These figures represent comprehensive diagnostic workups and do not include the subsequent transplant, donor harvesting, or conditioning hospitalization. Each hospital provides an itemised written quotation based on the individual patient's medical history and required specialist investigations.
| Country | Approximate cost range |
|---|---|
| Turkey | €3,500 – €8,500 |
| United Kingdom | €8,000 – €18,000 |
| United States | €15,000 – €35,000 |
| Germany | €7,500 – €16,000 |
Several factors explain variations in pre-transplant recipient evaluation (bmt) cost. The primary determinant is the complexity of required pathology and molecular genetics: basic blood panels and ultrasound carry lower costs, whereas next-generation sequencing, flow cytometric MRD panels, PET-CT scans, and cardiac MRI increase the total. If the recipient requires urgent dental extractions, sinus clearance, or placement of a tunneled central venous catheter (such as a Hickman line) during the workup week, these interventions add to the baseline fee.
The consolidated pre-transplant recipient evaluation (bmt) price generally covers all baseline laboratory panels, imaging, organ function studies, and specialist reviews. International patient packages in Turkey commonly include airport transfers, hospital coordination, and medical interpretation. Before committing to travel, patients can review how the coordination process works to understand diagnostic scheduling and hospital admission pathways. International patient departments provide formal quotations following a preliminary records review via our free quote enquiry service.
Conditioning protocol options: how evaluation guides treatment intensity
One of the most critical outcomes of the recipient evaluation is matching the patient to the safest and most effective conditioning regimen. Conditioning intensity is not one-size-fits-all; it must balance anti-tumour potency against the recipient's physiological reserves.
| Conditioning protocol | Best suited to | Typical limits |
|---|---|---|
| Myeloablative conditioning (MAC) | Younger recipients with normal organ function (HCT-CI score 0–1) and aggressive leukaemia | High organ toxicity; requires optimal cardiac ejection fraction and normal pulmonary diffusion |
| Reduced-intensity conditioning (RIC) | Older patients (frequently over 55–60) or those with mild organ comorbidities (HCT-CI score 2–3) | Relies heavily on donor graft-versus-tumour immunity; slightly higher early relapse rates |
| Non-myeloablative conditioning (NMA) | Frail recipients or heavily pre-treated individuals with substantial organ impairments | Minimal anti-tumour cell kill; carries higher risk of graft rejection without prolonged immunosuppression |
If evaluation reveals borderline lung function (such as a DLCO below 60%) or mild left ventricular impairment, the multidisciplinary committee will often shift the strategy from myeloablative conditioning to a reduced-intensity approach, protecting the patient from organ failure while preserving the curative potential of the donor stem cells.
Who is eligible for BMT, and what findings pause or prevent transplantation?
Good candidates for bone marrow transplantation are patients with hematologic malignancies or non-malignant marrow disorders whose underlying disease is under sufficient control and whose vital organs can tolerate conditioning and prolonged pancytopenia. Performance status is formally scored using the Karnofsky Performance Scale (KPS) or Eastern Cooperative Oncology Group (ECOG) scale; patients generally require a KPS score of 70% or higher (or ECOG 0–1) to proceed safely.
The evaluation may reveal absolute or relative contraindications. Absolute contraindications include uncontrolled active systemic infections, severe irreversible organ dysfunction (such as end-stage renal disease without planned tandem transplant, decompensated cirrhosis, or severe heart failure), uncontrolled psychiatric illness that impairs treatment adherence, or refractory haematologic disease that has completely escaped therapy. Relative contraindications—such as active dental caries, latent CMV or viral hepatitis reactivation, or mild nutritional depletion—typically pause the schedule rather than cancel it, allowing clinicians to treat the issue before conditioning begins.
The evaluation process step by step: from initial bloods to transplant clearance
The pre-transplant workup is executed systematically over five to seven working days to ensure all results are verified before inpatient admission:
- Day 1 (Arrival and baseline profiling): Initial consultation with the consultant haematologist, extensive fasting blood panels, viral serologies, HLA confirmation testing, and urine collection.
- Day 2 (Organ functional testing): Transthoracic echocardiogram, ECG, pulmonary function testing (spirometry and DLCO), and chest imaging (HRCT).
- Day 3 (Staging and invasive diagnostics): Bone marrow aspiration and trephine biopsy performed under local anaesthesia with sedation, followed by restaging PET-CT or diagnostic CT scans if indicated.
- Day 4 (Specialist consultations and dental clearance): Panoramic dental imaging and dental surgical check, alongside specialist reviews from cardiology, pulmonology, infectious diseases, and clinical psychology.
- Day 5 (Multidisciplinary review and vascular access): The institutional transplant board meets to consolidate findings and calculate the final comorbidity score. If cleared, the patient may undergo Hickman catheter placement under ultrasound and fluoroscopic guidance.
Travel schedule and pre-transplant recipient evaluation (bmt) recovery
International patients travelling to Turkey for pre-transplant evaluation should anticipate staying in Istanbul or Ankara for approximately seven to ten days for the diagnostic phase. Most investigations are performed on an outpatient basis while staying at a nearby hotel, though patients with advanced symptoms may be admitted to an inpatient room from arrival. Scheduling pre-transplant recipient evaluation (bmt) Turkey appointments requires coordination between your home haematologist and the receiving transplant centre to ensure recent medical records are reviewed in advance.
Because this phase consists of diagnostic investigations rather than surgery, pre-transplant recipient evaluation (bmt) recovery is primarily related to minor procedural discomfort. Following a bone marrow biopsy, patients may experience mild local tenderness and bruising at the posterior iliac crest for two to three days, which responds well to paracetamol. If a central venous catheter (Hickman line) is inserted at the end of the evaluation week, the neck and chest insertion sites require careful sterile dressing care and rest for 24 to 48 hours. Centres providing oncology treatments in Turkey assign international coordinators to assist with hospital transfers, medical translation, and appointment scheduling.
Potential risks and complications of pre-transplant investigations
Diagnostic evaluation is safe, but certain procedures carry recognized clinical risks. Professional bodies such as the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) and the EBMT outline standard precautions for pre-transplant diagnostics:
- Bone marrow biopsy risks: Localised discomfort, hematoma formation, and rarely local infection or persistent bleeding, particularly in thrombocytopenic patients requiring platelet transfusion support before the procedure.
- Radiological contrast reactions: Contrast agents used in CT scans carry small risks of allergic reaction or contrast-induced nephropathy, requiring pre-hydration in patients with marginal renal function.
- Central venous catheter placement risks: Insertion of a Hickman line carries risks of pneumothorax, arterial puncture, bleeding, catheter malposition, or early exit-site infection.
- Psychological strain: Undergoing extensive staging tests while awaiting transplant clearance creates acute emotional stress and anxiety for patients and family members, underscoring the necessity of psychosocial support services.
How to choose an accredited bone marrow transplant centre in Turkey
Selecting the right transplant centre is critical for patient safety and successful outcomes. When evaluating Turkish hospitals, patients should prioritize facilities accredited by the Joint Accreditation Committee ISCT-Europe & EBMT (JACIE). JACIE accreditation confirms that the hospital adheres to strict international quality management standards across clinical care, stem cell collection, processing, and laboratory testing.
Essential features of a high-quality BMT department include dedicated HEPA-filtered positive-pressure isolation rooms, on-site flow cytometry and molecular biology laboratories, a 24-hour intensive care unit experienced in oncologic emergencies, and a formal multidisciplinary transplant committee that reviews every recipient. Red flags include facilities without formal accreditation, clinics quoting flat prices without reviewing bone marrow reports, lack of dedicated haematology intensive care, or pressure to transfer funds before a haematologist has evaluated your medical history.
Understanding how it works from initial case review to post-workup discharge helps patients maintain realistic expectations throughout the preparatory week. You can submit your current medical summaries, imaging reports, and recent blood counts through our free quote portal to receive a preliminary specialist assessment.
Key questions to ask your transplant team
- Is the bone marrow transplant programme and cellular therapy laboratory JACIE-accredited?
- What specific tests will be performed during my evaluation week, and which will be repeated on arrival?
- Who serves on the multidisciplinary committee that determines my eligibility and conditioning regimen?
- What infection-control measures and air-filtration standards are used in the transplant unit?
- What occurs if an unexpected finding, such as a dormant infection or lung abnormality, is detected during the evaluation?
- Will my central venous catheter be placed immediately following evaluation, or upon formal inpatient admission?
Hospitals with Oncology in Turkey
Frequently asked questions
Pre-transplant recipient evaluation (bmt) is a detailed medical workup performed before bone marrow or stem cell transplantation. It involves heart and lung function tests, organ scans, infectious disease screening, dental checks, and disease staging to ensure the recipient can safely tolerate conditioning chemotherapy and engraftment.
While no assessment predicts every individual outcome, the workup significantly reduces preventable treatment toxicities. By identifying hidden infections, cardiac or pulmonary limitations, and kidney vulnerabilities before high-dose conditioning begins, haematologists can adjust chemotherapy doses, treat active issues in advance, or select reduced-intensity protocols.
Pre-transplant recipient evaluation (bmt) cost in Turkey typically ranges from €3,500 to €8,500, compared with €8,000 to €18,000 in the UK and higher in the United States. The total fee depends on whether specialised molecular assays, repeat bone marrow biopsies, or extended specialist consultations are required.
The comprehensive evaluation usually takes five to seven business days as an outpatient or short inpatient stay. Patients undergo imaging, laboratory panels, and specialist visits during the first three days, after which the transplant committee reviews the consolidated findings to determine final eligibility.
A patient may be paused or declined if tests reveal uncontrolled active infections, severe irreversible organ dysfunction such as heart failure or advanced pulmonary fibrosis, refractory disease progression, or poor performance status that makes surviving conditioning chemotherapy unlikely.
Most investigations, including blood draws, echocardiograms, and chest imaging, cause little to no discomfort. The primary invasive test is a bone marrow aspiration and biopsy, which is conducted under local anaesthesia with mild sedation to keep patients comfortable and takes approximately twenty to thirty minutes.
Recovery from the evaluation itself is rapid because most investigations are non-invasive. Patients may feel mild aching at the bone marrow biopsy site for two to three days, easily managed with paracetamol. Once cleared, patients proceed directly to central line placement and conditioning.
Conditioning chemotherapy suppresses white blood cells and damages oral mucosa, turning minor dental decay or gum inflammation into life-threatening bloodstream infections. A full dental examination and panoramic X-ray identify and resolve hidden cavities or abscesses before immunosuppression starts.
The evaluation tests remain largely the same, but the clearance thresholds differ. Full myeloablative conditioning demands robust heart, lung, and kidney function, whereas reduced-intensity conditioning accommodates older patients or those with moderate organ impairment identified during pre-transplant scoring.
The multidisciplinary transplant committee meets to review all diagnostic findings, calculate comorbidity scores, and confirm donor compatibility. If approved, the patient is scheduled for central line insertion, admission to the protective isolation ward, and the start of pre-transplant conditioning therapy.
Patient stories